{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T19:35:57Z","timestamp":1785612957861,"version":"3.56.0"},"reference-count":36,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"vor","delay-in-days":181,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["alz-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Alz &amp;amp; Dem Diag Ass &amp;amp; Dis Mo"],"published-print":{"date-parts":[[2017,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>Performance of the amyloid tracer [<jats:sup>18<\/jats:sup>F]flutemetamol was evaluated against three pathology\u00a0standard of truth (SoT) measures including neuritic plaques (CERAD \u201coriginal\u201d and \u201cmodified\u201d and the amyloid component of the 2012 NIA\u2010AA guidelines).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>After [<jats:sup>18<\/jats:sup>F]flutemetamol imaging, 106 end\u2010of\u2010life patients who died underwent postmortem brain examination for amyloid plaque load. Blinded positron emission tomography scan interpretations by five independent electronically trained readers were compared with pathology measures.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>By SoT, sensitivity and specificity of majority image interpretations were, respectively, 91.9% and 87.5% with \u201coriginal CERAD,\u201d 90.8% and 90.0% with \u201cmodified CERAD,\u201d and 85.7% and 100% with the 2012 NIA\u2010AA criteria.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>The high accuracy of either CERAD criteria suggests that [<jats:sup>18<\/jats:sup>F]flutemetamol predominantly reflects neuritic amyloid plaque density. However, the use of CERAD criteria as the SoT can result in some false\u2010positive results because of the presence of diffuse plaques, which are accounted for when the positron emission tomography read is compared with the 2012 NIA\u2010AA criteria.<\/jats:p><\/jats:sec>","DOI":"10.1016\/j.dadm.2017.06.001","type":"journal-article","created":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T17:15:17Z","timestamp":1498929317000},"page":"25-34","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":65,"title":["Performance of [<sup>18<\/sup>F]flutemetamol amyloid imaging against the neuritic plaque component of CERAD and the current (2012) NIA\u2010AA recommendations for the neuropathologic diagnosis of Alzheimer's disease"],"prefix":"10.1002","volume":"9","author":[{"given":"Stephen","family":"Salloway","sequence":"first","affiliation":[{"name":"Neurology and the Memory and Aging Program, Butler Hospital, Warren Alpert Medical School, Brown University Providence RI USA"},{"name":"Department of Neurology and Psychiatry Warren Alpert Medical School, Brown University Providence RI USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose E.","family":"Gamez","sequence":"additional","affiliation":[{"name":"Galiz Research, LLC Miami Springs FL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Upinder","family":"Singh","sequence":"additional","affiliation":[{"name":"Geriatric Solutions, LLC Las Vegas NV USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl H.","family":"Sadowsky","sequence":"additional","affiliation":[{"name":"Division of Neurology Nova SE University Fort Lauderdale FL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Villena","sequence":"additional","affiliation":[{"name":"Premiere Research Institute West Palm Beach FL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marwan N.","family":"Sabbagh","sequence":"additional","affiliation":[{"name":"Division of Neurology Barrow Neurological Institute Phoenix AZ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas G.","family":"Beach","sequence":"additional","affiliation":[{"name":"Banner Alzheimer's Institute Phoenix AZ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranjan","family":"Duara","sequence":"additional","affiliation":[{"name":"Mount Sinai Medical Center, Wien Center for Alzheimer's Disease and Memory Disorders Miami Beach FL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam S.","family":"Fleisher","sequence":"additional","affiliation":[{"name":"Banner Alzheimer's Institute Phoenix AZ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirk A.","family":"Frey","sequence":"additional","affiliation":[{"name":"Department of Radiology (Nuclear Medicine) University of Michigan Ann Arbor MI USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuzana","family":"Walker","sequence":"additional","affiliation":[{"name":"Division of Psychiatry University College London and North Essex Partnership University NHS Foundation Trust London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arvinder","family":"Hunjan","sequence":"additional","affiliation":[{"name":"Hertfordshire Partnership University NHS Foundation Trust Essex UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yavir M.","family":"Escovar","sequence":"additional","affiliation":[{"name":"VERITAS Research Miami Lakes FL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc E.","family":"Agronin","sequence":"additional","affiliation":[{"name":"Mental Health and Clinical Research Miami Jewish Health Systems Miami FL USA"},{"name":"University of Miami Miller School of Medicine Miami FL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel","family":"Ross","sequence":"additional","affiliation":[{"name":"Memory Enhancement Center Eatontown NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Bozoki","sequence":"additional","affiliation":[{"name":"Department of Neurology, Cognitive and Geriatric Neurology Team Michigan State University East Lansing MI USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Akinola","sequence":"additional","affiliation":[{"name":"Kennington Health Centre Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiong","family":"Shi","sequence":"additional","affiliation":[{"name":"Division of Neurology Barrow Neurological Institute Phoenix AZ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rik","family":"Vandenberghe","sequence":"additional","affiliation":[{"name":"Department of Neurology University Hospitals Leuven Leuven Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milos D.","family":"Ikonomovic","sequence":"additional","affiliation":[{"name":"Department of Neurology University of Pittsburgh Pittsburgh PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul F.","family":"Sherwin","sequence":"additional","affiliation":[{"name":"Life Sciences GE Healthcare Marlborough MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gill","family":"Farrar","sequence":"additional","affiliation":[{"name":"Life Sciences GE Healthcare Amersham Buckinghamshire UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian P.L.","family":"Smith","sequence":"additional","affiliation":[{"name":"Life Sciences GE Healthcare Amersham Buckinghamshire UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Buckley","sequence":"additional","affiliation":[{"name":"Life Sciences GE Healthcare Amersham Buckinghamshire UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dietmar Rudolf","family":"Thal","sequence":"additional","affiliation":[{"name":"Department of Pathology University Hospitals Leuven Leuven Belgium"},{"name":"Department of Neuroscience KU\u2010Leuven Leuven Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Zanette","sequence":"additional","affiliation":[{"name":"Life Sciences GE Healthcare Marlborough MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"Curtis","sequence":"additional","affiliation":[{"name":"Compass Research Orlando FL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,7]]},"reference":[{"key":"e_1_2_7_2_1","volume-title":"Robbins Pathologic Basis of Disease","author":"Cotran R.","year":"1999"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00308476"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.22.4.410"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2010.2008"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(12)70142-4"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(11)70077-1"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.22068"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.112.114785"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2014.4144"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awn016"},{"key":"e_1_2_7_12_1","unstructured":"FDA. US Prescribing information for Neuraceq 2016 n.d. Available at:http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/204677s012lbl.pdf. Accessed March 20 \u00a02017."},{"key":"e_1_2_7_13_1","unstructured":"EMA. Neuraceq EU Summary of Product characteristics 2016 n.d. Available at:http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_\u2010_Product_Information\/human\/002553\/WC500162592.pdf. Accessed March 20 \u00a02017."},{"key":"e_1_2_7_14_1","unstructured":"FDA. US Prescribing information for Amyvid 2013 n.d. Available at:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/202008s020lbl.pdf. Accessed March 20 \u00a02017."},{"key":"e_1_2_7_15_1","unstructured":"FDA. US Prescribing information for Vizamyl 2017 n.d. Available at:http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/203137s008lbl.pdf. Accessed March 16 \u00a02017."},{"key":"e_1_2_7_16_1","unstructured":"EMA. Vizamyl EU Summary of Product characteristics 2017 n.d. Available at:http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_\u2010_Product_Information\/human\/002557\/WC500172950.pdf. Accessed March 20 \u00a02017."},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40336-015-0102-6"},{"key":"e_1_2_7_18_1","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s13550-014-0037-3","article-title":"In\u00a0vivo PET imaging of beta\u2010amyloid deposition in mouse models of Alzheimer's disease with a high specific activity PET imaging agent [18F]flutemetamol","volume":"4","author":"Snellman A.","year":"2014","journal-title":"EJNMMI Res"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2011.10.007"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2015.05.018"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.58.12.1791"},{"key":"e_1_2_7_22_1","first-page":"142","article-title":"The consortium to establish a registry for Alzheimer's disease (CERAD). Part II. standardization of the neuropathologic assessment of Alzheimer's disease","volume":"46","author":"Mirra S.","year":"1991","journal-title":"Neurology"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1097\/MNM.0000000000000633"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40478-016-0399-z"},{"key":"e_1_2_7_25_1","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.neuroimage.2008.05.012","article-title":"Antemortem MRI based STructural Abnormality iNDex (STAND)\u2010scores correlate with postmortem Braak neurofibrillary tangle stage","volume":"42","author":"Vemuri P.","year":"2011","journal-title":"Neuroimage"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.115.161927"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.112.115006"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/ene.12102"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.114.142109"},{"key":"e_1_2_7_30_1","unstructured":"Ikonomovic MD Abrahamson EE Buckley CJ Mathis CA Klunk WE Farrar G. Contribution of neuritic and diffuse plaques to signal derived from CN\u2010Flutemetamol: a preliminary study in AD autopsy brains. Human Amyloid Imaging 2017 Meeting Abstract 2017:150."},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awv050"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-150732"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2015.00147"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(13)70044-9"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nicl.2015.10.007"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12149-017-1154-7"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurobiolaging.2009.04.002"}],"container-title":["Alzheimer's &amp; Dementia: Diagnosis, Assessment &amp; Disease Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352872917300398?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352872917300398?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1016%2Fj.dadm.2017.06.001","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1016\/j.dadm.2017.06.001","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1016\/j.dadm.2017.06.001","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1016\/j.dadm.2017.06.001","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T20:08:28Z","timestamp":1760386108000},"score":1,"resource":{"primary":{"URL":"https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/10.1016\/j.dadm.2017.06.001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["10.1016\/j.dadm.2017.06.001"],"URL":"https:\/\/doi.org\/10.1016\/j.dadm.2017.06.001","archive":["Portico"],"relation":{},"ISSN":["2352-8729","2352-8729"],"issn-type":[{"value":"2352-8729","type":"print"},{"value":"2352-8729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"2017-07-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}